*OPTIMIZATIONS IN APPLIED MACHINE LEARNING*
***Research Article | Volume 5 | Issue 5 | Nov 2025***
*Received: 22 Sep 2025 | Revised: 29 Sep 2025*
*Accepted: 15 Oct 2025 | Published Online: 02 Nov 2025*

# Graph Neural Network-based Drug-Target Interaction Prediction for Precision Medicine

Yuhan Dai[1], Li Wei[2] and Chen Yu[3],*

[1] Biostats & Data Management, Arrowhead Pharmaceuticals, Pasadena, CA, 91105, United States

[2] Institute of Emerging AI Technologies, Guiyang University, Guiyang, 550025, China

[3] Advanced Computing and Systems Institute, Yantai University, Yantai, 264005, China

[*]Corresponding Author, Email: yu.chen@yantai.edu.cn

Abstract: Drug-target interaction (DTI) prediction is central to precision medicine because it supports target prioritization, drug repurposing, and patient-specific therapeutic design. Existing computational approaches, however, often struggle with sparse interaction labels, heterogeneous biological evidence, and the nonlinear topology of drug-target networks. This paper proposes a Graph Neural Network (GNN)-based DTI prediction framework that represents drugs and targets as nodes in a bipartite biological graph and learns interaction-aware embeddings through message passing. By integrating drug descriptors, target features, structural similarity, and graph connectivity, the framework captures relationships that are difficult for similarity-based, matrix-factorization, or purely tabular models to express. A case study using simulated biochemical descriptors illustrates the modeling workflow, evaluation metrics, and limitations of baseline prediction. The results emphasize that graph-based representation learning can provide a more flexible foundation for DTI screening and precision-medicine decision support.

**Keywords:** *Drug-Target Interaction; Precision Medicine; Graph Neural Networks; Prediction Accuracy; Biological Networks*

## 1. Introduction

Drug-target interaction (DTI) prediction uses computational models to estimate whether a drug compound is likely to bind to, modulate, or otherwise affect a biological target. Reliable DTI prediction can shorten early-stage drug discovery, support drug repurposing, and help prioritize therapeutic hypotheses before expensive laboratory validation. The task remains difficult because biological systems are high-dimensional, interaction labels are incomplete, and data sources such as chemical descriptors, protein sequences, omics profiles, and network topology are heterogeneous. These challenges make reproducibility and generalization central requirements for any clinically useful DTI model.

Recent DTI research has moved from single-source similarity scoring toward heterogeneous representation learning. Network integration methods such as DTINet use multiple biological information sources to infer low-dimensional drug and target representations [1]. Transformer-based and deep-learning systems, including MolTrans, DeepPurpose, CCL-DTI, GraphormerDTI, MGNDTI, AttentionSiteDTI, and CAT-DTI, further improve interaction modeling by combining molecular representation learning, attention mechanisms, contrastive learning, multimodal fusion, and domain adaptation [2][3][4][5][6][7][8][9]. Together, these studies show that DTI prediction benefits from models able to combine biochemical features with relational structure, while also exposing the need for stronger interpretability and validation across datasets.

Graph Neural Networks (GNNs) are well suited to this setting because they learn from both node attributes and graph connectivity. Foundational studies have clarified the expressive power, benchmarking practice, and application scope of GNNs across molecular, recommendation, time-series, and matching tasks [10][11][12][13][14][15][16][17]. For DTI prediction, the advantage is direct: drugs, proteins, and known interactions can be represented as a biological graph, allowing message passing to propagate evidence through chemically or functionally related neighborhoods. At the same time, scaling GNNs for biomedical deployment requires efficient training and resource-aware model design, a concern also reflected in recent work on dynamic dropout and Transformer compression [27][29].

The motivation for the proposed framework also reflects adjacent trends in biomedical sensing, multimodal AI, and validation science. Midinfrared, terahertz, and graphene-based sensing platforms are expanding the kinds of fine-grained biochemical signals available to computational models [18][21][25][28], while energy-efficient edge reconstruction points to deployment settings where complex models must operate under practical computing constraints [20]. Multimodal medical-image analysis and multi-task visual prediction demonstrate the broader value of integrating heterogeneous evidence streams [23][24]. Meanwhile, process-based environmental modeling and field validation

studies emphasize that predictive models must be tested beyond their development data [19][22][26][30], and inverse-parameter identification in mechanics illustrates how latent properties can be inferred from limited observations when the modeling assumptions are explicit [31]. These perspectives motivate a DTI framework that treats prediction accuracy, computational efficiency, and validation rigor as connected design requirements.

The rest of the paper is organized as follows. Section 2 reviews DTI prediction methods and their limitations. Section 3 presents the proposed GNN-based framework. Section 4 describes the case study and evaluation design. Section 5 discusses the implications, limitations, and deployment considerations. Section 6 concludes the paper and outlines future research directions.

## 2. Background

### *2.1 Drug-Target Interaction Prediction*

Drug-Target Interaction (DTI) Prediction is a crucial task in the field of computational drug discovery that involves identifying potential interactions between drug compounds and biological targets, typically proteins. This prediction is vital for understanding the efficacy of drugs, repurposing existing drugs, and discovering new therapeutic targets.

The primary objective of DTI is to determine whether a given drug compound and a biological target will interact significantly, which implies that the compound will have a biological effect on the target. Formally, the problem can be framed as a binary classification problem, where the inputs are drug-target pairs, and the outputs are interaction labels, either indicating an interaction (positive) or not (negative).

Mathematically, suppose we have a set of drug compounds $D = \{d_1, d_2, \ldots, d_n\}$ and a set of biological targets $T = \{t_1, t_2, \ldots, t_m\}$. The DTI prediction task aims to learn a function $f: D \times T \rightarrow \{0,1\}$ that predicts whether a drug-target pair $(d_i, t_j)$ interacts.

One popular approach to DTI prediction is to represent drugs and targets using feature vectors. Let $x_d$ denote the feature vector for a drug $d$ and $x_t$ for a target $t$. The prediction function can be represented as:

$$y_{ij} = f\left(x_{d_i}, x_{t_j}\right) \tag{1}$$

where $y_{ij} \in \{0,1\}$ indicates the presence or absence of an interaction.

A common method to model $f$ is through similarity-based approaches, where the similarity between drugs and between targets is used. The similarity $S_D(d_i, d_j)$ between drugs and the

similarity $S_T(t_i, t_j)$ between targets can be calculated using various metrics like the Tanimoto coefficient or cosine similarity. Formally:

$$S_D(d_i, d_j) = \frac{x_{d_i} \cdot x_{d_j}}{\|x_{d_i}\| \ \|x_{d_j}\|} \tag{2}$$

$$S_T(t_i, t_j) = \frac{x_{t_i} \cdot x_{t_j}}{\|x_{t_i}\| \ \|x_{t_j}\|} \tag{3}$$

Matrix factorization techniques are also widely used for DTI prediction. Let $Y \in \mathbb{R}^{n \times m}$ be the interaction matrix, where element $y_{ij}$ denotes the interaction between drug $d_i$ and target $t_j$. Matrix factorization aims to approximate $Y$ by decomposing it into two lower-dimensional matrices:

$$Y \approx UV^T \tag{4}$$

Here, $U \in \mathbb{R}^{n \times k}$ and $V \in \mathbb{R}^{m \times k}$, with $k$ being the number of latent factors. The interaction between a drug $d_i$ and a target $t_j$ can then be predicted by:

$$y_{ij} = u_i^T v_j \tag{5}$$

Another sophisticated approach involves training machine learning models, such as neural networks, to learn the complex patterns of interaction. A neural network can be designed with input as the concatenated vector $[x_{d_i}, x_{t_j}]$ and output a probability score indicating the likelihood of interaction:

$$P(y_{ij} = 1 | x_{d_i}, x_{t_j}) = \sigma(w^T [x_{d_i}; x_{t_j}] + b) \tag{6}$$

where $\sigma$ is the sigmoid activation function, $w$ is the weight vector, and $b$ is the bias.

Graph-based methods can also enhance DTI prediction by modeling the problem as a bipartite graph with drugs and targets as nodes and interactions as edges. Various graph-based algorithms can then be applied to predict potential interactions.

In summary, DTI prediction is a multifaceted problem involving the integration of chemical, biological, and computational techniques. With advances in deep learning and computational power, more sophisticated and accurate predictive models are continually being developed, fostering the field of personalized medicine and targeted therapies.

*2.2 Methodologies & Limitations*

Drug-Target Interaction (DTI) Prediction plays a pivotal role in computational drug discovery by exploring potential interactions between drug molecules and biological targets such as proteins. Various methodologies have been employed in this field, ranging from traditional machine learning techniques to advanced deep learning models, but they often come with notable limitations.

One conventional approach is similarity-based methods. Here, drugs and their corresponding targets are represented as feature vectors. The similarity between two drug compounds $d_i$ and $d_j$ can be quantified using the cosine similarity, often represented as:

$$S_D(d_i, d_j) = \frac{x_{d_i} \cdot x_{d_j}}{\|x_{d_i}\| \, \|x_{d_j}\|} \tag{7}$$

Likewise, the similarity between two targets $t_i$ and $t_j$ is calculated analogously:

$$S_T(t_i, t_j) = \frac{x_{t_i} \cdot x_{t_j}}{\|x_{t_i}\| \, \|x_{t_j}\|} \tag{8}$$

Although these methods leverage chemical and genomic similarities, they often struggle to generalize beyond known interactions due to sparse data. The curse of dimensionality poses a significant challenge as each similarity matrix grows quadratically with either the number of drugs or targets.

Matrix factorization is another prevalent technique. This method attempts to decompose a given interaction matrix $Y$, where $y_{ij}$ signifies an interaction between a drug $d_i$ and a target $t_j$, into two latent feature matrices $U$ and $V$:

$$Y \approx UV^T \tag{9}$$

In this factorization, $U \in \mathbb{R}^{n \times k}$ and $V \in \mathbb{R}^{m \times k}$, while $k$ is the dimensionality of the latent space. The interaction prediction can then be computed as:

$$y_{ij} = u_i^T v_j \tag{10}$$

Despite its efficacy, matrix factorization assumes linear interactions, which may not always capture the complexity of drug-target interactions, and it also suffers from overfitting, especially with sparse datasets.

Machine learning techniques, particularly neural networks, provide another layer of complexity. In these models, the input comprises the concatenated feature vectors of drugs

and targets $[x_{d_i},\ x_{t_j}]$ . The interaction is then modeled by a neural network predicting the probability of interaction as:

$$P\left(y_{ij} = 1 | x_{d_i}, x_{t_j}\right) = \sigma\left(w^T\left[x_{d_i}; x_{t_j}\right] + b\right) \tag{11}$$

Here, $\sigma$ represents the sigmoid activation function. Although neural networks accommodate non-linear relationships, they require substantial data for training and can be computationally expensive.

Emerging graph-based methods represent the drugs and targets in a bipartite graph, utilizing graph neural networks (GNNs) to infer interactions by learning from topological structures. Formally, interactions as edges in these methods can be formulated as:

$$h_i' = \text{AGGREGATE}\left(h_j : j \in \mathcal{N}(i)\right) \tag{12}$$

$$h_i = \text{COMBINE}(h_i, h_i') \tag{13}$$

In summary, existing DTI methods offer complementary strengths, but persistent challenges remain: sparse labels, high-dimensional features, nonlinear biological mechanisms, computational cost, and weak generalization across datasets. These limitations motivate a graph-based framework that can preserve relational structure while integrating drug and target attributes in a unified predictive model.

## 3. The proposed method

### *3.1 Graph Neural Networks*

Graph Neural Networks (GNNs) represent a groundbreaking approach in the field of machine learning, specifically designed to handle graph-structured data. Unlike traditional neural networks that operate on fixed-size inputs, GNNs are capable of capturing the dependencies and relationships inherent in data organized in graphs. A graph $G = (V, E)$ consists of nodes $V$ and edges $E$ , where edges signify connections between pairs of nodes.

The core concept behind GNNs lies in leveraging both the features associated with the nodes and the graph topology to propagate information across the graph layers. At each layer of a GNN, node features are updated by aggregating and transforming the features of neighboring nodes. This aggregation and transformation process enables the network to learn high-level representations of each node that incorporate information from its local neighborhood.

Consider a node $v_i$ with initial feature vector $h_i^0$ . In a standard GNN layer, the node features are updated through two main operations: aggregation and combination.

The aggregation operation can be expressed as:

$$a_i^{(l)} = \text{AGGREGATE}(\{h_j^{(l-1)} : j \in \mathcal{N}(i)\}) \tag{14}$$

where $\mathcal{N}(i)$ denotes the set of neighbors of node $i$. This operation involves collecting and summarizing information from neighboring nodes, typically through operations like sum, mean, or max pooling.

Subsequently, the combination operation integrates the aggregated features with the node's own features:

$$h_i^{(l)} = \text{COMBINE}(h_i^{(l-1)}, a_i^{(l)}) \tag{15}$$

A common practice in GNNs is to apply a linear transformation followed by a non-linear activation, which can be described as:

$$h_i^{(l)} = \sigma(W^{(l)} \cdot \begin{bmatrix} h_i^{(l-1)} \\ a_i^{(l)} \end{bmatrix} + b^{(l)}) \tag{16}$$

Here, $W^{(l)}$ represents the learnable weight matrix at layer $l$, $b^{(l)}$ denotes the bias vector, and $\sigma$ is a non-linear activation function, such as ReLU.

In addition to node-level tasks like node classification, GNNs are highly suitable for graph-level tasks, including graph classification. Through message passing processes, such as the one outlined above, GNNs are remarkably effective at capturing the intricate structural information that defines graph-level properties.

To compute graph-level features, GNN layers can be stacked multiple times to enlarge the effective neighborhood of each node, effectively capturing long-range dependencies. The final graph representation can be obtained by pooling the representations of all nodes in the graph:

$$h_G = \text{READOUT}(\{h_i^{(L)} : i \in V\}) \tag{17}$$

where READOUT is a permutation invariant function, often a simple operation like averaging or sum, operating on the final hidden representations of nodes outputted by the last GNN layer (layer $L$).

Formally, the entire GNN can be represented by iteratively applying these update rules across layers:

$$H^{(l)} = f^{(l)}(H^{(l-1)}, G) \tag{18}$$

where $H^{(l)}$ is the matrix containing all node representations at layer $l$. The iterative updates capture both structural and feature-based dependencies within the graph data.

Finally, the power of GNNs is largely attributed to their capacity to integrate node features and graph topology, thereby enabling them to learn complex, non-linearly separable relationships in graph-structured datasets. While GNNs provide exceptional capabilities for applications ranging from social network analysis to molecular chemistry, challenges such as scaling to large graphs, efficiently handling dynamic graphs, and designing task-specific GNN architectures remain active areas of research.

*3.2 The Proposed Framework*

The task of Drug-Target Interaction (DTI) Prediction has significantly evolved with the advent of Graph Neural Networks (GNNs), which offer a robust framework for handling the intricate relationships in molecular data. At its core, DTI involves the identification of potential interactions between drug compounds and biological targets. This task can be modeled as a binary classification problem, formally expressed as a function $f: D \times T \rightarrow \{0,1\}$ , predicting whether a pair $(d_i, t_j)$ interacts.

To effectively address this problem using GNNs, it is essential to represent the drugs and targets as nodes within a bipartite graph $G = (V, E)$ , where $V = D \cup T$ . Nodes associated with drugs and targets are interconnected through edges representing their potential interactions. In this context, the initial feature vectors for each drug and target can be denoted as $h_d^0$ and $h_t^0$ , respectively.

A GNN processes this graph through layered message-passing steps, allowing the aggregation of information from neighboring nodes. For any given drug node $v_d$ and target node $v_t$ , their features are updated by defining an aggregation function that collects information from neighboring nodes:

$$a_d^{(l)} = \text{AGGREGATE}(\{h_t^{(l-1)}: t \in \mathcal{N}(d)\}) \tag{19}$$

where $\mathcal{N}(d)$ denotes the neighboring target nodes linked to drug node $d$ . The next step is to combine the aggregated features with the drug's current features, which can be expressed as:

$$h_d^{(l)} = \text{COMBINE}(h_d^{(l-1)}, a_d^{(l)}) \tag{20}$$

This combination is often realized through a linear transformation followed by a non-linear activation function, encapsulated in the formula:

$$h_d^{(l)} = \sigma(W^{(l)} \cdot [\begin{matrix} h_d^{(l-1)} \\ a_d^{(l)} \end{matrix}] + b^{(l)}) \tag{21}$$

where $W^{(l)}$ is the learnable weight matrix at layer $l$ , and $\sigma$ is a non-linear activation function such as ReLU.

After multiple layers of updating, the model captures rich node representations that incorporate both structural and feature information. To predict DTI, the final representation for pairs of drug and target nodes needs to be pooled, leading us to define a readout function that compiles node-level information into a graph-level feature representation:

$$h_G = \text{READOUT}(\{h_d^{(L)} : d \in D\}) \tag{22}$$

This pooled representation can be subsequently used in a prediction setting to evaluate the likelihood of interaction:

$$P(y_{ij} = 1 | h_G) = \sigma(w^T h_G + b) \tag{23}$$

where $y_{ij}$ indicates whether drug $d_i$ interacts with target $t_j$, $w$ is the weight vector, and $b$ is the bias.

Moreover, by employing GNNs, we can effectively exploit local neighborhoods for each drug and target across the graph, thereby enhancing the model's performance in recognizing complex interaction patterns. As we iterate through multiple layers, the GNN's ability to propagate and integrate feature information enables the formulation of intricate, non-linear relationships inherent in DTI prediction.

Ultimately, the key strength of GNNs in DTI prediction arises from their capability to merge important node features with the structural nuances of the underlying graph, leading to models that are both expressive and powerful in capturing drug-target interactions. Through continued advancements and refinements in GNN architectures, the predictive accuracy in DTI tasks will further improve, propelling forward the field of computational drug discovery.

*3.3 Flowchart*

The proposed workflow begins by collecting drug descriptors, target features, and known interaction labels, then organizing them as a drug-target graph. Node features are encoded, message passing is applied to learn interaction-aware representations, and a prediction layer estimates the probability of interaction for each candidate pair. The workflow also includes validation against baseline models and error analysis so that model performance can be interpreted rather than reported as a single accuracy score. Figure 1 illustrates the complete pipeline.




**Figure 1:** Flowchart of the proposed Graph Neural Networks-based Drug-Target Interaction Prediction

## 4. Case Study

*4.1 Problem Statement*

In this case, we aim to predict drug-target interactions using a mathematical model based on various biochemical and computational parameters. The interaction between a drug and its target protein can be influenced by several factors, including molecular geometry, binding affinity, and electrostatic interactions. We will utilize a nonlinear regression model to estimate the probability of interaction based on selected features derived from drug and target characteristics.

Let $x$ represent a vector of features extracted from drug compound descriptors such as molecular weight $x_1$, LogP value $x_2$, and number of hydrogen bond donors $x_3$. Define the target features also as a vector, including its molecular weight $y_1$, isoelectric point $y_2$, and number of aromatic rings $y_3$. Our objective function can be expressed as:

$$P(I) = \sigma(\beta_0 + \beta_1 x_1 + \beta_2 x_2 + \beta_3 x_3 + \gamma_1 y_1 + \gamma_2 y_2 + \gamma_3 y_3) \tag{24}$$

where $P(I)$ is the probability of interaction, $\sigma$ is the logistic function given by:

$$\sigma(z) = \frac{1}{1 + e^{-z}} \tag{25}$$

Next, we incorporate a distance-based metric to account for molecular conformation. The Euclidean distance $d$ between the drug and target feature vectors can be computed as:

$$d = \sqrt{(x_1 - y_1)^2 + (x_2 - y_2)^2 + (x_3 - y_3)^2} \tag{26}$$

This distance contributes to our interaction probability, leading to an additional term in our model:

$$P(I) = \sigma(\beta_0 + \beta_1 x_1 + \beta_2 x_2 + \beta_3 x_3 - \delta d) \tag{27}$$

To refine the model, we can introduce a nonlinear interaction term. This term can be defined as the product of feature pairs, facilitating the exploration of synergetic effects:

$$P(I) = \sigma(\beta_0 + \sum_{i=1}^{3} \beta_i x_i + \sum_{j=1}^{3} \gamma_j y_j + \sum_{i=1}^{3}\sum_{j=1}^{3} \theta_{ij} x_i y_j) \tag{28}$$

Furthermore, we account for potential noise in our observations using a Gaussian distribution, where the likelihood of observing data $D$ given parameters $\theta$ can be modeled as:

$$\mathcal{L}(D|\theta) = \prod_{k=1}^{N} \frac{1}{\sqrt{2\pi\sigma^2}} e^{-\frac{(D_k - P(I_k))^2}{2\sigma^2}} \tag{29}$$

This allows us to derive the maximum likelihood estimates of our parameters. By iterating through the optimization process, we aim to achieve better predictions of drug-target interactions. Ultimately, all parameters used in this model, along with their specific definitions and associated values, are summarized in Table 1.

**Table 1**: Parameter definition of case study

| Parameter | Value | Description | Source |
|---|---|---|---|
| Molecular Weight (Drug) | N/A | Weight of the drug molecule | Drug Compound Descriptors |
| LogP Value | N/A | Partition coefficient of the drug | Drug Compound Descriptors |
| Hydrogen Bond Donors (Drug) | N/A | Number of hydrogen bond donors in drug | Drug Compound Descriptors |
| Molecular Weight (Target) | N/A | Weight of the target protein | Target Features |
| Isoelectric Point (Target) | N/A | Isoelectric point of the target | Target Features |
| Number of Aromatic Rings (Target) | N/A | Number of aromatic rings in target protein | Target Features |
| Euclidean Distance (\(d\)) | N/A | Distance between drug and target feature vectors | Distance Metric |
| N/A | N/A | Gaussian distribution likelihood | Noise Model |

This case study applies the proposed GNN-based approach to a controlled DTI prediction setting involving biochemical and computational descriptors such as molecular geometry, binding affinity, hydrophobicity, and electrostatic interaction proxies. The goal is to show how drug and target features can be represented jointly, how nonlinear interactions can be incorporated, and how graph-based learning differs from traditional methods that rely mainly on independent feature vectors or linear assumptions. The

comparative analysis highlights both the promise of GNN-based representation learning and the need for careful validation when synthetic data are used.

*4.2 Results Analysis*

To illustrate the evaluation workflow, synthetic datasets were generated to simulate molecular features, including molecular weight, LogP values, hydrogen-bond descriptors, and target-related physicochemical properties. A logistic regression baseline was trained on the generated training set and evaluated on a held-out test set. Accuracy, true-positive rate, false-positive rate, ROC behavior, and predicted-probability distributions were examined together because a single metric can be misleading when class balance or ranking quality is weak. Figure 2 visualizes the resulting accuracy, ROC curve, feature correlation, and probability distribution.




**Figure 2:** Simulation results of the proposed Graph Neural Networks-based Drug-Target Interaction Prediction

**Table 2**: Simulation data of case study

| Parameter | Value | N/A | N/A | N/A |
|---|---|---|---|---|
| Model Accuracy | 1.0 | N/A | N/A | N/A |
| LogP Value | 0.2 | N/A | N/A | N/A |
| Molecular Weight | 500 | N/A | N/A | N/A |
| True Positive Rate | 1.0 | N/A | N/A | N/A |
| Receiver Operating Characteristic (AUC) | 0.48 | N/A | N/A | N/A |
| False Positive Rate | 0.400 | N/A | N/A | N/A |

Table 2 summarizes the simulation outcomes. The baseline achieves high threshold-based accuracy in this synthetic setting, but the ROC AUC of 0.48 indicates weak ranking ability and suggests that the apparent accuracy is not sufficient evidence of robust predictive performance. The narrow predicted-probability range, approximately 0.400 to 0.575, further shows that the classifier has limited confidence separation between positive and negative cases. These results support the need for richer feature integration and graph-aware modeling, while also underscoring that future empirical validation should use larger, externally benchmarked DTI datasets.

**5. Discussion**

The proposed GNN framework offers several advantages for DTI prediction. By representing drugs and targets as nodes in a bipartite graph, the model can aggregate information from chemically similar compounds, functionally related proteins, and known interaction neighborhoods. Message passing allows nonlinear relational patterns to be learned rather than imposed through fixed similarity scores or matrix-factorization assumptions. This structure is especially useful in precision-medicine contexts, where candidate interactions may depend on weak signals distributed across multiple biological evidence sources. The framework also creates a natural basis for adding interpretability modules, because predictions can be traced to node features, neighboring interactions, and graph pathways that contribute to the final score.

Several limitations should be noted. First, a bipartite drug-target graph may not capture all higher-order biological context, including pathway membership, disease phenotypes, and gene-regulatory relationships. Second, model quality depends strongly on the completeness and reliability of interaction labels; sparse or biased training data can lead to overfitting and poor external validity. Third, deeper GNN architectures can be computationally expensive and may oversmooth node representations if not regularized carefully. Fourth, interpretability remains challenging because message passing distributes evidence across graph neighborhoods. Finally, the simulation results in this paper are illustrative rather than definitive, so future work should validate the framework on public benchmark datasets and prospective experimental data.

## 6. Conclusion

This paper proposed a Graph Neural Network-based framework for DTI prediction in precision medicine. The framework models drugs and targets as a biological graph, integrates heterogeneous descriptors, and uses message passing to learn interaction-aware representations. The polished case study clarifies that baseline accuracy alone is not enough to establish predictive reliability, especially when ranking metrics and probability separation remain weak. Overall, the study positions GNN-based representation learning as a promising foundation for DTI screening, while emphasizing the need for stronger external validation, richer biological context, and more interpretable deployment pipelines.

## Funding

Not applicable

## Author Contribution

Conceptualization, Yuhang Dai and Li Wei; writing-original draft preparation, Yuhang Dai and Chen Yu; writing-review and editing, Li Wei and Chen Yu. All authors read and agreed to the published final manuscript.

## Data Availability Statement

The data are accessible upon request.

## Conflict of Interest

The authors declare no conflict of interest.

References

[1] Y. Luo et al., "A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information," Nature Communications, vol. 8, 2017.

[2] K. Huang et al., "MolTrans: Molecular Interaction Transformer for drug-target interaction prediction," Bioinformatics, vol. 37, 2020.

[3] K. Huang et al., "DeepPurpose: a deep learning library for drug-target interaction prediction," Bioinformatics, vol. 36, 2020.

[4] A. Dehghan et al., "CCL-DTI: contributing the contrastive loss in drug-target interaction prediction," BMC Bioinformatics, vol. 25, 2024.

[5] Y. Liu et al., "Neighborhood Regularized Logistic Matrix Factorization for Drug-Target Interaction Prediction," PLoS Computational Biology, vol. 12, 2016.

[6] M. Gao et al., "GraphormerDTI: A graph transformer-based approach for drug-target interaction prediction," Computers in Biology and Medicine, vol. 173, 2024.

[7] L. Peng et al., "MGNDTI: A Drug-Target Interaction Prediction Framework Based on Multimodal Representation Learning and the Gating Mechanism," Journal of Chemical Information and Modeling, 2024.

[8] M. Yazdani-Jahromi et al., "AttentionSiteDTI: an interpretable graph-based model for drug-target interaction prediction using NLP sentence-level relation classification," Briefings in Bioinformatics, vol. 23, 2022.

[9] X. Zeng et al., "CAT-DTI: cross-attention and Transformer network with domain adaptation for drug-target interaction prediction," BMC Bioinformatics, vol. 25, 2024.

[10] K. Xu et al., "How Powerful are Graph Neural Networks?" International Conference on Learning Representations, 2018.

[11] V. P. Dwivedi et al., "Benchmarking Graph Neural Networks," Journal of Machine Learning Research, 2023.

[12] J. Zhou et al., "Graph Neural Networks: A Review of Methods and Applications," AI Open, 2018.

[13] P.-E. Sarlin et al., "SuperGlue: Learning Feature Matching With Graph Neural Networks," Computer Vision and Pattern Recognition, 2019.

[14] W. Wu et al., "A Comprehensive Survey on Graph Neural Networks," IEEE Transactions on Neural Networks and Learning Systems, 2019.

[15] S. L. Batzner et al., "E(3)-equivariant graph neural networks for data-efficient and accurate interatomic potentials," Nature Communications, 2021.

[16] W. Fan et al., "Graph Neural Networks for Social Recommendation," The Web Conference, 2019.

[17] Z. Wu et al., "Connecting the Dots: Multivariate Time Series Forecasting with Graph Neural Networks," Knowledge Discovery and Data Mining, 2020.

[18] X. Deng, S. Oda, and Y. Kawano, "Graphene-based midinfrared photodetector with bull's eye plasmonic antenna," Optical Engineering, vol. 62, no. 9, p. 097102, 2023.

[19] J. Li, T. B. Culver, C. R. Burgis, W. Zhang, and J. A. Smith, "Validating Nitrogen Removal Models with Field Bioretention Data," Journal of Environmental Engineering, vol. 150, no. 8, p. 04024037, 2024.

[20] H. Yan, "Real-Time 3D Model Reconstruction through Energy-Efficient Edge Computing," Optimizations in Applied Machine Learning, vol. 2, no. 1, 2022.

[21] X. Deng, L. Li, M. Enomoto, and Y. Kawano, "Continuously frequency-tuneable plasmonic structures for terahertz bio-sensing and spectroscopy," Scientific Reports, vol. 9, no. 1, p. 3498, 2019.

[22] J. Li, T. B. Culver, P. P. Persaud, and J. M. Hathaway, "Developing nitrogen removal models for stormwater bioretention systems," Water Research, vol. 243, p. 120381, 2023.

[23] H. Yan and D. Shao, "Multimodal Medical Image Analysis: Integrating LLM and RAG Deep Learning Strategies," Journal of Advances in Information Technology, vol. 16, no. 4, pp. 568-581, 2025, doi: 10.12720/jait.16.4.568-581.

[24] X. Deng and Y. Kawano, "Surface plasmon polariton graphene midinfrared photodetector with multifrequency resonance," Journal of Nanophotonics, vol. 12, no. 2, p. 026017, 2018.

[25] J. Li, "Nitrogen Removal Models for Stormwater Bioretention Systems," Ph.D. dissertation, University of Virginia, 2023.

[26] H. Yan and D. Shao, "Enhancing Transformer Training Efficiency with Dynamic Dropout," arXiv:2411.03236, 2024. https://doi.org/10.48550/arXiv.2411.03236.

[27] X. Deng, M. Simanullang, and Y. Kawano, "Ge-core/a-Si-shell nanowire-based field-effect transistor for sensitive terahertz detection," Photonics, vol. 5, no. 2, p. 13, 2018.

[28] Z. Luo, H. Yan, and X. Pan, "Optimizing Transformer Models for Resource-Constrained Environments: A Study on Model Compression Techniques," Journal of Computational Methods in Engineering Applications, pp. 1-12, Nov. 2023, doi: 10.62836/jcmea.v3i1.030107.

[29] J. Li and T. B. Culver, "Review of process-based nitrogen model for agricultural fields with implications for nitrogen simulations in stormwater BMPs," Environmental Modelling & Software, vol. 151, p. 105363, 2022.

[30] Y. Zhang and A. Needleman, "On the identification of power-law creep parameters from conical indentation," Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, vol. 477, no. 2252, p. 20210233, 2021.

[31] Y. Zhang and A. Needleman, "Characterization of plastically compressible solids via spherical indentation," Journal of the Mechanics and Physics of Solids, vol. 148, p. 104283, 2021.